British
and Irish Legal Information Institute
Freely Available British and Irish Public Legal Information
[
Home]
[
Databases]
[
World Law]
[
Multidatabase Search]
[
Help]
[
Feedback]
United Kingdom Intellectual Property Office Decisions
You are here:
BAILII >>
Databases >>
United Kingdom Intellectual Property Office Decisions >>
COSMACEUTICAL (Trade Mark: Opposition) [1999] UKIntelP o34899 (8 October 1999)
URL: http://www.bailii.org/uk/cases/UKIntelP/1999/o34899.html
Cite as:
[1999] UKIntelP o34899
[
New search]
[
Printable PDF version]
[
Help]
COSMACEUTICAL (Trade Mark: Opposition) [1999] UKIntelP o34899 (8 October 1999)
For the whole decision click here: o34899
Trade mark decision
- BL Number
- O/348/99
- Decision date
- 8 October 1999
- Hearing officer
- Mr M Foley
- Mark
- COSMACEUTICAL
- Classes
- 03, 05
- Applicants
- Universal Products (Lytham) Manufacturing Ltd
- Opponents
- Bioglan Laboratories Ltd
- Opposition
- Section 3(1)(a), (b), (c) and (d) Section 3(3)(b) and 3(6)
Result
Section 3(1)(a) (b) and (c) - Opposition failed.
Section 3(1)(d) - Opposition failed. Evidence insufficient to establish that word is generic in the UK.
Section 3(3)(a) - Opposition failed as a result of failure under 3(1).
Section 3(6) - Opposition failed. Claim not established.
Points Of Interest
-
1. Internet extracts showing use on US Web Sites may be insufficient to establish that a word has generic connotations in the UK. Use on UK Web Sites would of course be a different matter.
-
2. See also DERMACEUTICAL O/349/99
Summary
The opponents claimed that the mark is made up of COSME (indicating cosmetics) and CEUTICAL (indicating pharmaceuticals) and that the term is used within the industry to refer to cosmetics with pharmaceutical qualities. The evidence filed by the opponents, which included Internet use, was considered by the Hearing Officer to be insufficient to establish the opponents claims that the term was generic in the UK or that it was sufficiently non-distinctive or descriptive to fall foul of Sections 3(1)(a), (b) (c) and (d).